(Q53540821)

15 May 2018

title

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). (English)

1 reference

15 May 2018

1 reference

Freedman BI

1

1 reference

15 May 2018

Wuerth JP

2

1 reference

15 May 2018

Cartwright K

3

1 reference

15 May 2018

Bain RP

4

1 reference

15 May 2018

Dippe S

5

1 reference

15 May 2018

Hershon K

6

1 reference

15 May 2018

Mooradian AD

7

1 reference

15 May 2018

Spinowitz BS

8

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

15 May 2018

Contemporary Clinical Trials

published in

1 reference

15 May 2018

volume

20

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

493-510

1 reference

15 May 2018

Blood glucose control and diabetic complications

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Diabetic regulation and its relationship to microangiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Nonenzymatic glycosylation and the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Advanced glycosylation end products in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I-iothalamate

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Properties of permuted-block randomization in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Adjusting for early treatment termination in comparative clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Unbalanced repeated-measures models with structured covariance matrices.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

Implementation of group sequential logrank tests in a maximum duration trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900024-0

7 January 2021

10.1016/S0197-2456(99)00024-0

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018